Skye Bioscience

Skye’s CBeyond Trial examines weight loss effects of nimacimab alone and combined with semaglutide.

A review of Skye’s highly peripherally-restricted CB1 inhibitor and its advantages relative to the incretin class of anti-obesity drugs and small-molecule CB1 inhibitors, with recent preclinical data.

Skye Bioscience targets the endocannabinoid system (ECS) for therapeutic benefits, supported by scientific research.

Skye’s CMO and CSO discuss the mechanistic differences of nimacimab, a peripherally-restricted CB1-inhibiting antibody.

in vivo: The advancement of nimacimab as a weight loss mechanism within the growing space of anti-obesity therapeutics.

Project Ascend is Skye’s 90-day roadmap to validate higher-exposure dosing for nimacimab and strengthen the clinical and translational evidence behind peripheral CB1 inhibition in obesity.

xtalks: Skye Bioscience is pioneering a new approach to obesity drug development, focusing on peripheral CB1 inhibition to improve metabolic health.

A new class of weight loss drugs are reshaping obesity treatment while also raising important questions about safety, side effects, and long-term use.

The letter outlines Skye’s 2025 progress, the role of CB1, and future plans.

CEO Punit Dhillon discusses Skye’s accomplishments in 2024 and the execution plans for 2025, in particular announcing data from its Phase 2 study of nimacimab for weight loss.

Evidence suggests that dietary changes, more than reduced physical activity, are the primary factor in rising obesity rates, exploring how what people eat may matter more than how much they move.

A report by the Lancet Commission argues that BMI alone is misleading and proposing a shift toward assessing health impacts like organ function, fat distribution, and risk markers to decide when weight becomes a medical concern.

Tu Diep, Skye Bioscience's COO discusses his lifelong passion, interest and work leading up to the clinical drug development journey of lead asset nimacimab.

Skye Bioscience develops new mechanisms and drugs to address obesity and related metabolic conditions.

Skye Bioscience provides information about its company and operations.

Test description, update to the test description.

The company develops cannabinoid derivatives for glaucoma and other unmet medical needs.

Skye Bioscience outlines its privacy policy for visitor data collected through its website.